ArticleBMC cancer2026
A P4HA2 hypoxia signature derived from single cell atlas stratifies conserved subtypes with prognostic significance in cervical squamous cell carcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCervical cancer, especially cervical squamous cell carcinoma (CSCC), is a major public health issue in low- and middle-income countries, with advanced recurrence and metastasis linked to poor prognosis. It shows significant intra-tumoral phenotypic heterogeneity and plasticity.
methodsWe analyzed the single-cell RNA sequencing data of cervical squamous cell carcinoma available in the Gene Expression Database (GEO) and identified the tumor cell subtype exhibiting hypoxic characteristics. We extracted differentially expressed genes (HRDEGs) between this hypoxia-related cluster and other tumor cells. Based on the CSCC bulk RNA sequencing data from the Cancer Genome Atlas (TCGA), this subtype was confirmed to be closely associated with poor prognosis in CSCC.101 combinations consisting of 10 machine learning models were used for screening prognostic biomarkers in HRDEGs, and a hypoxia signature was established by multivariate COX regression.
resultsThe hypoxia signature, validated using external GEO datasets, was significantly correlated with tumor invasiveness. Further analysis demonstrated that immune infiltration and responses to both chemotherapy and immunotherapy are associated with the hypoxia signature. In addition, the key gene P4HA2 in the hypoxia signature has been demonstrated to be involved in the regulation of malignant phenotypes of tumor cells and the regulation of HIF-1α stability.
conclusionsOverall, this hypoxia signature is a promising independent prognostic factor, provides potential biomarkers for the prognosis of CSCC and may guide future investigations into patient stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.